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Background and Objectives:
 
 Since conventional ran-
domized clinical trials often do not reflect the real
world circumstances of prescribing behavior and pa-
tient outcomes, the use of retrospective administrative
claims databases (RACD) has become more common in
treatment cost comparisons among alternative pharma-
ceutical compounds. Several recent RACD studies have
compared treatment costs for depressed patients pre-
scribed SSRIs such as fluoxetine, sertraline and paroxe-
tine. These cost comparisons have reached mixed con-
clusions. To begin to explain and reconcile the mixed
SSRI cost comparison evidence, we undertake a variety
of alternative multivariate analyses using a publicly
available RACD.
 
Methods and Data:
 
 The 1995 to 1996 data encom-
passes a time period when all three SSRIs had become
well-established agents. We report and compare results
from multivariate linear regressions, logistic regres-
sions, ordered probits and sample selectivity models,
and examine robustness when adjustments are made for
outlier observations and skewed distributions.
 
Results and Conclusions:
 
 While choice of initial SSRI is
nonrandom, the effect of sample selectivity on total de-
pression-related and total health care expenditure is
neutral across SSRIs. Although most cost measures are
numerically greatest for fluoxetine, depression-related
outpatient and hospitalization costs do not significantly
differ by choice of initial SSRI. These findings are ro-
bust to alternative assumptions, specifications, and pro-
cedures. Antidepressant medication costs, however, are
significantly higher when fluoxetine is the initial SSRI
rather than sertraline or paroxetine, reflecting the larger
proportion of fluoxetine patients prescribed a daily
dosage of two or more capsules. Both total depression-
related and total health care log–transformed costs are
significantly lower for sertraline than fluoxetine.
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Introduction
C
 
onventional randomized clinical trials (RCTs)
may not accurately reflect the relative real-world
effectiveness of alternative medical treatments in
the environment of actual practice. Health services
researchers have increasingly utilized retrospective
administrative claims databases (RACDs) to make
more realistic treatment cost comparisons. While
relatively inexpensive and containing information
on very large numbers of patients, RACDs typi-
cally are unable to provide information on patient
illness severity, physician/patient/provider relation-
ships, and clinical outcome. Analyses based on
RACDs require methodological care due to possi-
ble biases related to nonrandom patient assign-
ment [1–3]. In large part because of their real-
world foundations, RACDs have been the basis
for numerous economic analyses comparing dif-
ferent treatment alternatives.
A number of recently published studies employ-
ing RACDs have compared treatment costs for
depressed patients prescribed tricyclic antidepres-
sants (TCAs), and/or one of the three leading selec-
tive serotonin reuptake inhibitors (SSRIs)—fluox-
etine, sertraline, and paroxetine [4–17]. Although
the prevailing evidence suggests that SSRIs are
cost-effective treatment alternatives to TCAs, to
date the published evidence comparing health care
costs among the different SSRIs has not been as
consistent.
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Since depression is one of the most prevalent
mental disorders [18], carries a substantial eco-
nomic burden [19], and is effectively treated with
SSRIs [20–23], it is important to continue to as-
sess the relative cost-effectiveness of the different
SSRIs. Given the mixed results in the literature, it
is equally important to critique these studies and
clarify how methodological differences can influ-
ence results.
Common analysis issues are: the effects of com-
paring newly approved with more established
agents [3,6], the sensitivity of results to infrequent
high-cost outlier observations (e.g., hospitaliza-
tion costs) and overfitting [24,25], the effects of
nonrandom unobserved factors that affect both
treatment choice and cost (i.e., patient-provider-
physician relationship) [3,5,7], and the robustness
and sensitivity of conclusions to alternative statis-
tical procedures and assumptions that may affect
the measurement of variability and power to de-
tect a statistical difference [24].
In this study, we build on our previous research
[6] and examine the robustness and sensitivity of
direct treatment cost comparisons among fluoxe-
tine, sertraline, and paroxetine using a wide vari-
ety of alternative statistical methods. Our analysis is
based on 1995 to 1996 RACD from MarketScan
 
TM
 
,
a publicly available dataset distributed by Med-
Stat, used in several of the aforementioned studies.
To understand better several important meth-
odological issues inherent in the analysis of RACDs,
we begin by reviewing two published articles.
 
The Sclar et al. Study
 
Based on nonpublicly available RACD data from
a large HMO in the US Pacific Northwest, Sclar et
al. [8] compare 12-month direct depression-related
health care costs following an index prescription
(defined here and throughout as the initial pre-
scription following at least 6 months with no pre-
scription for a depressive disorder) for one of
three SSRIs (fluoxetine, paroxetine, or sertraline)
between January 1, 1989 and March 31, 1994.
They report that, based on their multivariate re-
gression analyses, treatment with paroxetine or
sertraline resulted in significantly increased total
depression-related health care costs relative to flu-
oxetine. They attribute the cost differentials to
greater titration of sertraline and paroxetine rela-
tive to fluoxetine.
During the 5-year (60-month) time interval of
this study, fluoxetine was continuously available,
whereas sertraline was only available for the last
26 months (from February 1992), and paroxetine
the final 15 months (from January 1993) of the
study. As a result, many physicians and their
HMOs were not able to prescribe sertraline and
paroxetine in the beginning of the study period,
and may have had inadequate time to gain suffi-
cient experience with paroxetine and sertraline.
Moreover, to the extent physicians prescribed the
new antidepressants preferentially to those pa-
tients refractory to previous treatment, paroxetine
and sertraline may have been prescribed dispro-
portionately to patients having more difficult and
complex depressive disorders. This phenomenon
has been called channeling or allocation bias by
Egbert et al. [3], who documented that three anti-
depressants newly introduced into the Nether-
lands from 1994 to 1995 (mirtazapine, sertraline,
and venlafaxine) were disproportionately chan-
neled to patients who did not respond satisfacto-
rily to previous pharmacologic treatment. The
Sclar et al. [8] study offers some suggestive evi-
dence also supporting this channeling hypothesis.
In that study, patients treated with the newest
agents—sertraline and paroxetine—had depression-
related hospitalization costs that were more than 6
times those prescribed fluoxetine [6]. Problems as-
sociated with channeling could be reduced consid-
erably by basing treatment cost comparisons on
data from a time period during which all SSRIs
studied were well-established agents.
The health care cost data used in Sclar et al. [8]
are not based on actual costs, but on a notional
fixed fee schedule: $50 for each physician and psy-
chiatrist visit, $200 per hospital day, $250 per
psychiatric hospital day, and average wholesale
price (less rebate, but no dispensing fee) for each
30-day prescription.
To minimize the impact of unobserved disease
severity differences, Sclar et al. excluded patients
having various psychiatric comorbid conditions,
patients switching antidepressants, and patients
taking an antidepressant in the 6-month pretreat-
ment period. In addition, patients had to receive
three or more consecutive prescriptions for the
same antidepressant, which market research data
consistently indicate do not reflect the typical pa-
tient. To control further for unobserved severity
differences, the authors included as regressors in
multivariate analyses the number of concomitant
nonpsychiatric disease states, total 6-month pre-
treatment depression-related health care costs, and
whether the initial provider was a primary care
physician or a psychiatrist. It is worth noting that,
while broadly utilized in the literature as methods
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to control for unobserved severity differences, this
control is attained at the cost of additional as-
sumptions, often not verifiable.
Other researchers [7,26] have critiqued the Sclar
et al. [8] research methodology. Excluding pa-
tients who switched antidepressants and those
who discontinued treatment overlooks important
real world phenomena with significant cost impli-
cations [1,7]. Hylan et al. [7] note sample selectiv-
ity techniques could have been used which may
have reduced the influence of unobserved differ-
ences associated with nonrandom sampling. Con-
fining the cost comparisons to depression-related
costs omits possible offsets between other medical
costs and depression-related costs [26,27].
 
The Hylan et al. Study
 
Hylan et al. [7] report results from a publicly
available retrospective claims database (Market-
Scan
 
TM
 
), covering a much wider variety of provid-
ers and payers than Sclar et al. The claims are
based on actual amounts paid (insurer plus patient
copay) rather than notional fee schedules but are
again potentially compromised by the channeling
phenomenon, since the time period of study (1990–
94) included the introduction of paroxetine and
sertraline.
Hylan et al. separate total health care costs into
mental health and nonmental health, and employ
inclusion and exclusion criteria similar to Sclar et
al. but include switchers and those who had less
than three consecutive antidepressant prescrip-
tions. Based on univariate analyses, they report
that mean total health care costs and mean mental
health care costs are not significantly different
among fluoxetine, sertraline, paroxetine and the
TCAs. However, median total and mental health
care costs are significantly different: median men-
tal health care costs are highest for fluoxetine and
median total health care costs are highest for the
TCAs.
Hylan et al. highlight their use of a multivariate
two-stage statistical regression procedure that at-
tempts to account for nonrandom treatment choice
(sample selectivity). The procedure involves an ad-
justment for each patient, based on observable
characteristics, to control for unobserved differ-
ences that might be correlated with the choice of
antidepressant and health care expenditures. When
this procedure is employed and logarithms of costs
are the dependent variable, Hylan et al. find no
differences in (log) mental health care costs among
the SSRIs, but find significantly lower (log) total
health care costs for patients initiating therapy on
fluoxetine relative to sertraline. This difference in-
volving sertraline is apparently driven by lower
nonmental health care costs among fluoxetine pa-
tients. The latter finding contrasts with Sclar et al.
[8] who attributed the higher paroxetine and ser-
traline depression-related health care costs to SSRI
titration rate differences. This difference in con-
clusions and interpretations of sources of costs
differences well exemplifies the mixed evidence in
the literature.
The application of sample selectivity proce-
dures in the Hylan et al. study is seriously flawed.
The selectivity procedure requires initial estima-
tion of a model that characterizes factors affecting
nonrandom choice among TCAs and the three SSRIs
for each patient from 1990 to 1994. However,
Hylan et al. include observations for 1990 and
1991, years when fluoxetine was the only SSRI
available, and thus it was impossible for patients/
physicians to have chosen sertraline or, until
1993, paroxetine. This inappropriate incorpora-
tion of data from a time period when not all
choices were available undermines the attempt to
control for sample selectivity, and may help ex-
plain why the sample selectivity procedure was
statistically significant only for fluoxetine.
It is of course possible that unobserved factors
affect SSRI treatment choice in a nonrandom way,
and that this sample selectivity affects cost com-
parisons. Statistical tools have been designed that
attempt to overcome the effects of sample selectiv-
ity, such as the Heckman [28] procedure or the
propensity score method of Rubin [29]. The abil-
ity of these tools to control reliably for sample se-
lectivity, as well as the appropriate interpretation
of results, remains somewhat controversial [25,29–
34]. Nonetheless, because sample selectivity could
be present and important, in this paper we assess
the robustness of least squares findings when the
Heckman procedure is employed.
There are a number of other issues that arise
not only in the studies cited above, but also in
most RACD analyses. Health care expenditure
data are typically highly skewed and not normally
distributed. A small number of large-cost observa-
tions can have a critical impact on the size of the
estimated parameters and their statistical signifi-
cance (overfitting). While logarithmically trans-
forming health care expenditure data can reduce
the influence of outlier observations and make tra-
ditional statistical assumptions more plausible (e.g.,
normality of data and homoskedasticity of the
random disturbances), the robustness of parame-
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ter estimates and their statistical inference need to
be carefully examined in the context of potentially
influential observations [24,35–37]. Such robust-
ness checks are not generally reported in RACD
studies.
 
Objectives and Methods
 
Our objective is to begin to explain and reconcile
the mixed SSRI cost comparison evidence by ex-
amining the robustness of findings using a variety
of alternative methods for dealing with skewed
and nonrandom RACD data. We focus on com-
paring the treatment course, depression-related,
and total medical costs associated with patients di-
agnosed with depression who began treatment
with one of the three leading SSRIs in 1995, a time
by which all three had become established agents.
Since major changes involving the management of
treatment for depression and other illnesses have
occurred in recent years, use of 1995 to 1996 data
is also more likely to reflect the current environ-
ment than is the 1989 to 1994 data analyzed in
previous studies.
The publicly available fee-for-service Market-
Scan
 
TM
 
 medical claims database from MedStat, in-
cluding over 600,000 lives, was used to estimate
total and depression-related health care costs for
1995 and 1996. This database was also employed
by Hylan et al. [7], but with a 1990 to 1994 time
frame for patient selection. Definitions of selection
criteria used to obtain records of 2342 patients di-
agnosed with depression who began treatment
with an SSRI in 1995 are described below:
• Age 18–65 and a prescription for an antide-
pressant in 1995 [50,031 patients, 100.0%];
• Treatment with fluoxetine, paroxetine or ser-
traline and diagnosed with a depressive disor-
der (ICD-9 code of 296.2, 296.3, 300.4,
311.0) in 1995 [9990 patients, 20.0%];
• No antidepressant use in the 6-month period
prior to date of the index (first) SSRI prescrip-
tion [4410 patients, 8.8%];
• Continuous enrollment for 6 months prior to the
index SSRI prescription [3459 patients, 6.9%];
• No prescription for antipsychotics, mood sta-
bilizers, anticonvulsants, substance abuse agents,
or Parkinsonian agents at any time [3087 pa-
tients, 6.2%];
• No substance abuse diagnosis at any time
[3072 patients, 6.1%];
• Continuous enrollment in the health care plan
for 12 months after the index SSRI prescrip-
tion [2342 patients, 4.7%].
Variables were defined as follows:
• Antidepressant and Other Prescription Costs:
Total receipts to pharmacy 
 

 
 insurer 
 

 
 patient
copay, coinsurance and deductibles;
• Outpatient Visit Costs: Total payment to pro-
viders for outpatient professional services, in-
cluding laboratory costs, from deductibles, co-
insurance, copays, and insurance payments;
• Hospitalization Costs: Total payment to hos-
pitals and providers from all sources;
• Total Depression-Related Costs: Outpatient,
inpatient, and laboratory costs associated with
an ICD-9 depression diagnosis code (296.2,
296.3, 300.4, 311) and antidepressant phar-
maceutical costs during 12-month treatment
period;
• Total Health Care Costs: All outpatient, inpa-
tient, laboratory and pharmaceutical costs irre-
spective of diagnosis, including depression-
related treatment costs during 12-month treat-
ment period;
• Titration: Change in total daily dose from pre-
vious prescription by more than 
 

 
 5% on
same SSRI, for those patients having at least
two index SSRI prescriptions;
• Index Prescription: First prescription with flu-
oxetine, paroxetine, or sertraline from January
1 through December 31, 1995 after 6-month
antidepressant-free period;
• Pretreatment Period: 6-month period prior to
date of index (first) SSRI prescription;
• Treatment Period: 12-month period following
date of index (first) SSRI prescription;
• Switching: Change to another SSRI antidepres-
sant from the index SSRI in the 12-month
treatment period.
Univariate comparisons of means of categorical
variables are based on Cochran-Mantel-Haenszel
(CMH) chi-square tests, while those based on con-
tinuous variables employ analysis of variance (anova)
 
F
 
-tests. Comparisons of medians are based on the
nonparametric Brown-Mood median score test.
Multivariate linear and logistic regression pro-
cedures are employed, relating various measures
of health care costs (raw and log-transformed cost
dependent variables) to a set of explanatory vari-
ables. The explanatory variables allow for nonlin-
ear effects on costs, and include patient age (Age)
and its square (Agesq), gender (Female), the inter-
action of age and gender (Age*Female), the num-
ber of comorbid medical conditions and its square
(Comorbid, Comorbidsq), 6-months preperiod de-
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pression-related total health expenditures and its
square (Precost, Precostsq), 0–1 binary variables
for the index prescribing physician (Psyprovider),
and the index SSRI (fluoxetine, paroxetine, and
sertraline). This equation specification is a nonlin-
ear generalization of that by Sclar et al. [8]. The
reference case in these regressions is a male treated
by a nonpsychiatrist with fluoxetine. The vari-
ables are described in detail below.
Multivariate regressors were defined as follows:
• Age: Patient’s age in years at the time of index
SSRI prescription;
• Age Squared (Agesq): Square of a patient’s age,
allows for nonlinearity to more closely resem-
ble the rise in health care expenditures seen
with age;
• Comorbidity (Comorbid): Number of comor-
bid medical conditions based on the diagnostic
classification of ICD-9 codes into 17 major
disease categories. Multiple occurrences within
a diagnostic class are associated as one disease;
• Comorbidity Squared (Comorbidsq): Number
of comorbid medical conditions squared, al-
lows for nonlinearity to more closely resemble
the rise in health care expenditures seen in pa-
tients who have multiple diseases;
• Precost: Total depression-related health care
costs for the individual in the 6-month period
prior to index SSRI prescription;
• Precost Squared (Precostsq): Square of 6-month
pretreatment period depression-related health
care costs;
• Psychiatric Provider (Psyprovider): If index
physician is a psychiatrist value is 1; else 0;
• Paroxetine: Binary (0–1) variable that denotes
the prescription of (1) or absence (0) of an in-
dex SSRI prescription of paroxetine;
• Sertraline: Binary (0–1) variable that denotes
the prescription of (1) or absence of an index
SSRI prescription of sertraline;
• Fluoxetine: Both paroxetine and sertraline are
equal to 0 when fluoxetine is the index SSRI.
To determine whether a small number of out-
lier observations are influential and whether there
is possible overfitting [25], we utilize the Belsley,
Kuh, and Welsch (BKW) [35,36] procedure in
which an influential observation is identified by
having a studentized residual greater than two in
absolute value and an h-hat value 
 

 
 2*p/
 
n
 
, where
p is the number of parameters in the model and 
 
n
 
is the number of observations in the full sample re-
gression. Since the average value of h-hat over all
observations is p/
 
n
 
, the latter criterion selects ob-
servations whose influence on parameter estimates
is more than twice the average. The impact of in-
fluential observations is then assessed by compar-
ing parameter estimates and inference in the full
and trimmed sample regressions, where the latter
is the full sample minus the influential observa-
tions.
Although use of BKW in many applications can
help identify problematic observations, in the cur-
rent context such observations may well be real
and of great concern to managed care officials. In
general, trimming on the basis of only studentized
residuals will lead to consistent estimates only if
the cost data are symmetric, which typically does
not occur with health claims data. If the data were
log normally distributed, more of the grand mean
on the raw scale will be cut from the right tail than
the left, leading to biased estimates. Thus we do
not prefer trimmed estimates a priori. Rather, we
compare full and trimmed sample estimates, and if
they yield different inference, we use this as a heu-
risitic to warn of possible overfitting in the full
sample regressions. We implement this robustness
check both with the raw scale and logarithmically
transformed cost data [24,37].
To accommodate possible heteroskedasticity of
the disturbances, we employ the White procedure
for computing heteroskedasticity-robust standard
errors [36], and also implement the linear version
of the White test for homoskedasticity. As another
specification check, we evaluate the number of
predicted costs that are negative in the nonlog re-
gressions, since least squares estimation of the lin-
ear model does not ensure that all predicted values
for health care expenditures are positive.
Finally, since health care expenditure data is
highly skewed, we rank order the dataset into
quartiles, with the first quartile having the lowest
and the fourth having the highest health care
costs. We then estimate an ordered probit model
utilizing maximum likelihood methods, allowing
us to determine, e.g., the shift in the probability
distribution of being in the lowest or highest quar-
tile when one SSRI is prescribed at index rather
than another [36,38].
While we have reservations concerning the use-
fulness and reliability of the two-step sample selec-
tivity method procedure for making cost compari-
sons, for purposes of sensitivity analyses, we utilize
it. Explanatory variables in the first stage multino-
mial logit SSRI choice equations are similar to
those in Hylan et al. and include patient demo-
graphics, 0–1 binary variables for having ICD-9
diagnoses DX296.2, DX296.3, DX300.4, DX311
 Comparing SSRI Treatment Costs for Depression
 
213
 
and/or DX309 during the 12-month treatment
period, the number of psychotherapy visits in
the 6-month preperiod (Visit6), Psyprovider, and
whether the patient had a nonpsychiatric hospital-
ization in the 6-month pretreatment period (Hosp6).
The second stage estimations employ the same equa-
tion specifications as in the log linear multivariate
regressions, but add the inverse Mills ratio (lambda)
as a regressor, and employ robust standard error
calculations. Identification is attained in part by
excluding the diagnosis code, preperiod psycho-
therapy visits, and preperiod hospitalization vari-
ables from the second stage [39]. These excluded
variables have been reported to be statistically in-
significant predictors of healthcare utilization and
costs in other SSRI studies [7,40]. All computa-
tions were performed using the SAS System for
Windows, Version 6.12.
 
Results
 
Table 1 reports patient demographic characteris-
tics at time of index SSRI prescription, and clinical
course characteristics during the 12-month treat-
ment period for the 945 fluoxetine, 492 paroxe-
tine, and 905 sertraline individuals meeting study
inclusion criteria. There is no significant difference
among the SSRI cohorts in age, gender, index pro-
vider type, or the number of outpatient visits for
depression or all causes. Mean number of antide-
pressant prescriptions was higher for fluoxetine
patients than for paroxetine or sertraline patients
(
 
P
 
 
 

 
 .005 and 
 

 
 0.001, respectively). There was
notable titration in all cohorts. On average, slightly
more than 2% of patients were hospitalized for
depression, and approximately 8% were hospital-
ized for any reason.
Table 2 describes health care cost data during
the 6-month pretreatment and 12-month treat-
ment period; additional discussion of these data is
found in Russell et al. [6]. Mean and median pre-
treatment period outpatient health care expendi-
tures were similar. Although the sertraline cohort
had higher preperiod hospitalization costs, reflect-
ing a higher proportion of sertraline patients
hospitalized for depression prior to index SSRI
treatment, these differences were not statistically
significant. Mean and median outpatient depres-
sion-related and total medical costs during the 12-
month treatment period are similar across the SSRIs.
Depression-related hospitalization costs vary greatly
across patients with standard deviations being 7–11
times larger than means. Pharmaceutical costs are
significantly higher in the fluoxetine than in the
sertraline (
 
P
 
 
 

 
 .001) and paroxetine (
 
P
 
 
 

 
 .016)
cohorts. Right tail skewness is substantial in each
component, and in total health care costs, with
medians being much smaller than means, and
 
Table 1
 
Patient demographic and clinical characteristics
 
Demographic or Clinical Characteristics
Statistical Significance
(
 
P
 
-values for comparison of )
Fluoxetine 
 
n
 
 
 

 
 945
Paroxetine
 
n
 
 
 

 
 492
Sertraline
 
n
 
 
 

 
 905
Fluoxetine
vs Paroxetine
Fluoxetine
vs Sertraline
Paroxetine 
vs Sertraline
Demographic Variables:
Mean Age (sd) 41.3 (11.3) 41.7 (12.0) 41.6 (11.2) 0.498 0.592 0.486
Percent female 70.3 67.3 69.6 0.244 0.76 0.368
Percent index provider psychiatrist 34.7 30.5 31.3 0.107 0.116 0.762
Clinical Variables
Outpatient Treatment
Mean number (%) of depression-related
visits 6.8 (9.1) 7.1 (9.4) 6.7 (8.8) 0.612 0.762 0.451
Mean number (%) of visits for other causes 12.7 (12.7) 13.9 (16.5) 14.1 (14.8) 0.143 0.037 0.781
Mean number (%) of visits for all causes 19.1 (15.5) 20.5 (18.0) 20.3 (17.1) 0.918 0.68 0.81
Antidepressant Treatment
Mean dose in milligrams 24.7 (10.8) 24.4 (9.3) 71.1 (34.4) 0.941
 

 
0.001
 

 
0.001
Mean number of antidepressant Rxs 7.8 (4.9) 7.1 (4.5) 6.9 (4.7) 0.005
 

 
0.001 0.494
Number (%) patients titrated 411 (43.5) 175 (35.6) 430 (47.5) 0.004 0.084 0.001
If titrated, mean number of titrations 1.84 (1.23) 1.59 (1.16) 1.70 (1.19) 0.021 0.092 0.305
Treatment in Hospitals:
Number of patients (%) hospitalized for
depression 20 (2.1) 11 (2.2) 22 (2.4) 0.883 0.65 0.819
Number of patients (%) hospitalized for 
other causes 54 (5.7) 30 (6.1) 63 (7) 0.769 0.271 0.536
Number of patients (%) hospitalized for 
all causes 72 (7.6) 39 (7.9) 80 (8.8) 0.836 0.339 0.559
 
P
 
-values for comparisons of means of categorical variables based on CMH chi-square test, and for continuous variables on ANOVA F-test.
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measures of skewness being positive and large.
However, when either total depression-related or
total health care costs are log-transformed, mea-
sures of skewness fall close to zero, with slightly
negative values in most cases. Statistical test re-
sults based on assumed normality of raw scale
costs should therefore be interpreted cautiously.
Table 3 reports least square estimates of factors
affecting 12-month treatment period expenditures
for depression related and total health care, in dol-
lars, where the reference case is a male fluoxetine
patient treated by a nonpsychiatrist. With this lin-
ear specification and raw scale cost data, parame-
ter estimates in the total column are the sum of
parameters in the first three columns. Parameter
estimates indicate that outpatient and hospitaliza-
tion depression related health care costs are not
different among fluoxetine, paroxetine, and ser-
traline. While a number of factors significantly af-
fect outpatient expenditures, only pretreatment
cost and its square are predictive of hospitaliza-
tion costs in the treatment period. However, in the
antidepressant medication cost equation, when
controlling for other factors, pharmaceutical costs
 
Table 2
 
Depression-related and total health care costs during 6-month pre-treatment period and 12-month
treatment period
 
Treatment
Health Care Costs
Statistical Significance 
(
 
P
 
-values for comparison of)
Fluoxetine
 
n
 
 
 

 
 945
Paroxetine
 
n
 
 
 

 
 492
Sertraline
 
n
 
 
 

 
 905
Fluoxetine 
vs Paroxetine
Fluoxetine
vs Setraline
Paroxetine 
vs Sertraline
Depression-related pre-period health 
care costs:
Mean Costs (Standard Deviation)*
Outpatient/Laboratory 201.6 (461.6) 207.6 (430.7) 235.4 (562.0) 0.498 0.592 0.486
Hospitalization 32.9 (512.1) 54.2 (503.4) 124.3 (1108) 0.244 0.76 0.368
Pharmacotherapy (antidepressant) 0 0 0
Total 234.5 (715.5) 261.8 (698.2) 359.7 (1256) 0.107 0.116 0.762
Median Costs
 
†
 
Outpatient 35 38 40 0.727 0.28 0.586
Pharmacotherapy 0 0 0 n/a n/a n/a
Total 35 38 41 0.604 0.077 0.342
Depression-related health care costs— 
12-month treatment period
Mean Cost (Standard Deviation)*
Pharmaceutical 586.1 (429.6) 418.5 (319.7) 446.3 (341.6)
 

 
0.001
 

 
0.001 0.187
Outpatient/Laboratory 639.9 (1007) 684.7 (994.6) 629.9 (994.8) 0.420 0.831 0.328
Hospitalization 159.3 (1799) 128.2 (1227) 126.9 (978.7) 0.692 0.622 0.987
Total 1385 (2221) 1231 (1690) 1203 (1555) 0.140 0.037 0.788
Median Cost
 
†
 
Pharmaceutical 542.7 371.2 392.1
 

 
0.001
 

 
0.001 0.381
Outpatient/Laboratory 224 248.5 210 0.260 0.217 0.053
Total 868.1 692.6 735.3
 

 
0.001
 

 
0.001 0.323
Variance-Log total depression-related costs 1.001 1.268 1.153 n/a n/a n/a
Skewness-Total depression-related costs
Raw units 9.932 6.982 4.264 n/a n/a n/a
Log-transformed
 

 
0.253
 

 
0.261
 

 
0.185 n/a n/a n/a
Total health care costs—12-month 
treatment period
Mean Cost (Standard Deviation)*
Pharmaceutical 1166 (893.7) 1045 (1014.0) 1015 (856.0) 0.016
 

 
0.001 0.562
Outpatient/Laboratory 2468 (2919) 2486 (2567) 2528 (3491) 0.918 0.680 0.810
Hospitalization 1046 (9988) 555.5 (2483) 832.4 (3807) 0.199 0.504 0.472
Total 4680 (10,925) 4086 (4721) 4375 (6400) 0.197 0.429 0.534
Median Cost
 
†
 
Pharmaceutical 952 786 799 0.004
 

 
0.001 0.927
Outpatient/Laboratory 1578.000 1711 1664 0.564 0.484 0.807
Total 2739 2721 2659 0.927 0.429 0.562
Variance-Log total health care costs 0.937 0.897 0.935 n/a n/a n/a
Skewness-Total health care costs
Raw units 19.207 3.981 5.764 n/a n/a n/a
Log-transformed 0.037 0.248 0.004 n/a n/a n/a
 
*
 
P
 
-values for comparisons of means of categorical variables based on CMH chi-square test, and for continuous variables on ANOVA F-test.
 
†
 
Since 97.7% of sample was not hospitalized, median hospitalization cost is equal to 0 and not reported here. Tests for differences in medians are based on the non-
parametric Brown-Mood test (SAS procedure NPARIWAY).
n/a 
 

 
 not applicable.
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are significantly less for paroxetine ($164, 
 
P
 
 
 

 
.001) and sertraline ($140, 
 
P
 
 
 

 
 .001) when com-
pared to fluoxetine. For total depression-related
costs, expenditures are about $239 less for sertra-
line than fluoxetine (
 
P
 
 
 

 
 .01), but there is no sig-
nificant difference between paroxetine and fluox-
etine. When total health care costs are evaluated,
there is no significant difference in estimated costs
between the fluoxetine, paroxetine, and sertraline
cohorts. The adjusted R
 
2
 
 falls from 0.14 to 0.11
when nondepression related costs are incorpo-
rated into the medical care cost measure. Al-
though the linear cost specification does not en-
sure that all predicted costs are non-negative, this
becomes a practical issue only for hospitalizations,
where 434 of the 2342 observations (19%) have
negative predicted values.
Table 4 reports on the sensitivity of the magni-
tude and significance of the paroxetine and sertra-
line estimated parameters (relative to fluoxetine)
to alternative assumptions and specifications. The
top two panels report results with raw scale costs
as dependent variable, while the bottom two pan-
els are those with log-transformed costs.
The three important findings initially reported
in Table 3 based on raw scale costs are robust to
use of heteroskedasticity-consistent standard error
calculations and trimmed sample estimations. Spe-
cifically, as seen in the top two panels of Table 4,
relative to fluoxetine, antidepressant R
 
x
 
 costs are
significantly less for paroxetine and sertraline (
 
P
 
 
 

 
.001), total depression-related costs are signifi-
cantly less for sertraline (
 
P
 
 
 

 
 .05), but for total
health care costs there is no statistically significant
difference among the three SSRIs.
These findings are changed and sharpened con-
siderably when the dependent variable is log-
transformed costs. As seen in the bottom two pan-
els of Table 4, relative to fluoxetine, antidepres-
sant R
 
x
 
 costs are about 36% less for paroxetine
(
 
P
 
 
 

 
 .001) and 30% less for sertraline (
 
P
 
 
 

 
 .001).
With both trimmed samples and robust standard
errors, total depression-related log costs are about
17–18% less for paroxetine than with fluoxetine
(
 
P
 
 
 

 
 .01 with full sample, 
 
P
 
 
 

 
 .001 with trimmed
sample and robust standard errors), and about
20% less for sertraline than fluoxetine (
 
P
 
 
 

 
 .001).
Moreover, for total health care log costs, there is
no statistically significant difference between par-
oxetine and fluoxetine, but with sertraline these
log costs are about 9–10% less than with fluoxe-
tine as the index SSRI (
 
P
 
 
 

 
 .01). As documented
in the notes to Table 4, these differential log-costs
among SSRIs persist when the regressors precost
and its square are log-transformed as well.
To the extent total depression-related and total
health care costs exhibit statistically significant
differences therefore both Tables 3 and 4 identify
antidepressant R
 
x
 
 costs as a significant principal
driver of these differences.
Table 5 describes more detailed evidence re-
garding the underlying course of treatment and
cost consequences of choosing a particular index
SSRI. Logistic regression analyses demonstrate that
the only significant predictors of being hospital-
ized for depression are age and the square of pre-
 
Table 3
 
Least square estimates of factors affecting per capita 12-month treatment period expenditures* (reference case is 
male fluoxetine patient treated by non-psychiatrist
 
†
 
Effect on depression-related costs ($)
Outpatient Hospital
Antidepressant
Medication Total
Effect on total health
care costs ($)
Constant
 
120.73 172.9 197.651 249.83 722.95
Age (years) 28.182 0.07 15.793 45.041 13.13
Agesq 0.483 0.05 0.183 0.712 0.98
Female 213.88 15.64 51.72 281.24 156.22
Age*Female 4.86 2.23 0.63 3.26 31.37
Precost 0.443 0.142 0.01 0.0573 0.52
Precostsq‡ 19.463 14.873 2.152 2.44 34.251
Comorbid 24.6 1.6 25.142 51.34 412.691
Comorbidsq 0.17 3.93 2.101 2 49.912
Psyprovider 693.883 9.77 82.013 766.123 443.1
Paroxetine 69.42 35.01 163.873 129.46 672.79
Sertraline 23.86 74.62 140.503 238.992 607.20
Adj. R2 .2137 .0650 0.0604 0.1378 0.1086
Mean Predicted Costs 644.7 140.22 496.85 1281.77 4437.81
No. Predict 0 18 434 0 0 4
*1, 2, and 3 denote statistical significance at P-values less than or equal to 0.05, 0.01 and 0.001 respectively, based on t-tests.
†n  2342.
‡The coefficient of Precostsq is multiplied by E106.
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treatment costs, not the choice of index SSRI. The
probability of being titrated, all else equal, how-
ever, is significantly lower for paroxetine than flu-
oxetine (odds ratio of 0.725, P  .01), but there is
no difference between sertraline and fluoxetine.
The odds of being titrated are also higher if the in-
dex provider is a psychiatrist (odds ratio 1.447,
P  .001). The probability of a patient ever being
given a more costly SSRI prescription having two
or more tablets/capsules per day (rather than one
per day) is highly associated with choice of index
SSRI; the odds ratios relative to fluoxetine are
0.388 for paroxetine (P  .001) and 0.529 for ser-
traline (P  .001). The odds of receiving a multi-
ple tablet daily dose prescription are also higher
for patients having greater medical comorbidities
(P  .05) and a psychiatrist as the index provider
(odds ratio 1.747, P  .01). Patients with an in-
dex prescription for paroxetine are nearly twice as
likely to switch to another SSRI when compared
to fluoxetine patients (odds ratio 1.968, P  .001),
while sertraline patients are about a third more
likely to switch to another SSRI (odds ratio 1.359,
P  .05).
As an alternative to multivariate linear regres-
sions, Table 6 reports parameter estimates for the
ordered probit specification, in which expendi-
tures are ranked by quartile with 1 being the low-
est cost quartile and 4 the highest [36]. The signif-
icantly negative coefficient estimates indicate that
with the exception of outpatient costs, the hospi-
talization (P  .001), antidepressant (P  .001)
and total depression-related health care cost (par-
oxetine P  .05; sertraline P  .001) probability
distributions are shifted significantly out of the
highest quartile 4 and into quartile 3, and from
quartile 2 into the lowest cost quartile 1, when
paroxetine or sertraline is the index SSRI rather
than fluoxetine. Though not reported, qualita-
tively similar results were found when the cost
measure was total health care costs.
Table 7 presents results regarding the cost ef-
fects of possible nonrandom choice of index SSRI.
Entries in the first two columns show that while
only a few observed variables significantly affect
choice of index prescription, the SSRI choice is in
fact nonrandom. Those patients hospitalized with
a depression-related diagnosis in the 6-month pre-
period were more likely to be prescribed sertraline
than fluoxetine at index (P  .01), while the prob-
ability of being prescribed sertraline rather than
fluoxetine decreased as the number of preperiod
psychotherapy visits increased (P  .01). Sertra-
line was less likely to be the index SSRI when a di-
agnosis was major depressive disorder–recurrent
episode (P  .05). The significant negative inter-
cept term in the paroxetine equation (P  .01) is
consistent with paroxetine being less likely to be
the index SSRI than fluoxetine when the patient’s
diagnosis was major depressive disorder–single
episode. The global likelihood ratio test that the
odds of choosing any SSRI are even and unaf-
fected by the set of regressors is decisively rejected
(P  .001).
While choice of index SSRI appears to be non-
random, second stage OLS estimates of the log to-
tal medical cost equations indicate that the cost
consequences of this are neutral across SSRIs. In
particular, none of the second-stage coefficient es-
Table 4 Sensitivity of paroxetine and sertraline parameter 
estimates to alternative treatments of skewed data
Cost Estimates Relative 
to Fluoxetine*
Modification Paroxetine Sertraline
Linear, full sample, least squares,
robust standard errors:
Depression-Related
Outpatient 69.42 23.86
Hospital 35.01 74.62
Antidepressant Rx 163.873 140.503
Total 129.46 238.991
Total Health Care Costs 672.79 607.2
Linear, trimmed sample, least 
squares, robust standard errors:
Depression-Related†
Outpatient (n  2320) 50.95 35.44
Hospital (n  2342) 35.01 74.62
Antidepressant Rx (n  2342) 163.873 140.503
Total (n  2342) 129.46 238.991
Total Health Care Costs (n  2342) 672.79 607.20
Log costs, full sample, least squares, 
conventional standard errors:
Depression-Related
Outpatient 0.00 0.04
Hospital ($5) 0.00 0.00
Antidepressant Rx 0.363 0.303
Total‡ 0.172 0.203
Total Health Care Costs§ 0.06 0.092
Log costs, trimmed sample, least 
squares, robust standard errors:
Depression-Related†
Outpatient (n  2331) 0.00 0.07
Hospital ($5) (n  2330) 0.01 0.02
Antidepressant Rx (n  2340) 0.363 0.303
Total (n  2328)‡ 0.183 0.203
‘Total Health Care Costs (n  2327)§ 0.05 0.102
*1, 2, and 3 denote statistical significance at P-values less than or equal to 0.05,
0.01, and 0.001 respectively, based on z-test.
†Sample sizes when influential observations are deleted, based on the BKW
procedure, are denoted by n.
‡When regressors pre-cost and its square are log-transformed, the paroxetine
and sertraline estimates become 0.172 and 0.203 in the full sample, and
0.173 and 0.203 in the trimmed sample.
§When regressors pre-cost and its square are log-transformed, the paroxetine
and sertraline estimates become 0.06 and 0.092 in the full sample, and
0.06 and 0.102 in the trimmed sample.
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timates on lambda (the inverse Mills ratio vari-
able) is significantly different from zero at P 
.05. Similar results (not shown) occur when log
depression-related healthcare costs is the depen-
dent variable. Moreover, based on the Chow F-test
[36], with lambda excluded from each SSRI equa-
tion, the null hypothesis that all parameters (ex-
cept intercept terms) are equal across the three
SSRI equations is not rejected in the log depres-
sion related (F18,2312  1.265, P  .201) and in the
log total health care cost specifications (F18,2312 
1.309, P  .173). These latter results lend strong
empirical support for the various logarithmic cost
comparison findings reported in the bottom two
panels of Table 4, which incorporate these across
SSRI parameter restrictions implicitly.
Discussion
The publicly available data used in this health care
cost comparison among the three leading SSRIs
are from 1995 and 1996. With these data, we ob-
tain three sets of results that are robust across al-
ternative assumptions, specifications, and proce-
dures. First, as others have, we find substantial
unexplained variability in costs, both depression-
related and total health care, but particularly for
hospitalization costs. Second, depression-related
outpatient and hospitalization costs are generally
unaffected by choice of index SSRI. Depression-
related antidepressant costs, however, are signifi-
cantly lower when the index SSRI is sertraline or
paroxetine rather than fluoxetine. Total depres-
sion-related health care costs are significantly less
for sertraline than for fluoxetine (P  .05 raw
units, P  .001 in log costs), but evidence on
whether there is a significant difference in these
costs between paroxetine and fluoxetine is mixed
(no significance in raw cost units, P  .01 in log
costs). Third, in cases where the most inclusive
measure of direct medical costs is used (depression
plus nondepression related costs), total medical
costs are consistently less when sertraline is the in-
dex SSRI rather than fluoxetine, but only in the
various log-transformed cost equations is this dif-
ference statistically significant (P  .01); for par-
oxetine relative to fluoxetine, the difference in to-
tal medical costs is never significant.
The results reported here differ somewhat from
those of Sclar et al. [8] and Hylan et al. [7], who
reported significantly lower total depression-related
and lower total health care costs, respectively,
when fluoxetine was the index SSRI rather than
sertraline or paroxetine. While the Sclar database
is not publicly available, in this study we have uti-
lized the same Marketscan database used by Hy-
lan et al. except we have employed more recent
1995 to 1996 data. Although we are unable here
to demonstrate it definitively, we believe that since
fluoxetine was introduced in January 1988 and
sertraline and paroxetine were not introduced un-
til February 1992 and January 1993, the 1990 to
1994 Hylan et al. and the 1989 to 1994 Sclar cost
comparisons may be subject to a channeling bias
Table 5 Results from logistic regressions: SSRI hospitalization, titration, and prescription probabilities*†
Whether
Hospitalized
Whether
Titrated
Whether ever had Rx
with 2 or more SSRI 
Tablets per day
Whether 
Switched
Parameter Odds Ratio Parameter Odds Ratio Parameter Odds Ratio Parameter Odds Ratio
Constant 1.397 n/a 0.381 n/a 0.753 n/a 3.0813 n/a
Age 0.1351 n/a 0.007 n/a 0.004 n/a 0.048 n/a
Agesq 0.001 n/a 0.000 n/a 0.000 n/a 0.001 n/a
Female 0.994 0.370 0.517 0.597 0.468 0.626 0.527 1.693
Age*Female 0.005 n/a 0.009 n/a 0.005 n/a 0.017 n/a
Comorbid 0.309 n/a 0.055 n/a 0.1221 n/a 0.020 n/a
Comorbidsq 0.009 n/a 0.000 n/a 0.010 n/a 0.006 n/a
Precost 0.000 n/a 0.000 n/a 0.000 n/a 0.000 n/a
Precostsq‡ 0.0621 n/a 0.009 n/a 0.042 n/a 0.134 n/a
Psyprovider 0.017 0.983 0.3693 1.4473 0.5583 1.7473 0.066 1.068
Paroxetine 0.037 1.038 0.3222 0.7252 0.9473 0.3883 0.6773 1.9683
Sertraline 0.120 1.127 0.171 1.186 0.6373 0.5293 0.3071 1.3591
LR p-value§ 0.001 0.001 0.0001 0.0001
N 2342 2342 2342 2342
*1, 2, and 3 denote statistical significance at P-value less than or equal to 0.05, 0.01, and 0.001 respectively, based on z-test that parameter is zero, and/or that odds
ratio is one.
†The omitted category is a male, non-psychiatric provider, fluoxetine.
‡The coefficient on Precostsq in the OLS regressions is multiplied by E106.
§P-value of likelihood ratio test that all coefficients other than intercept are simultaneously equal to zero.
n/a  not applicable.
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favoring fluoxetine. That physicians have chan-
neled prescriptions for the newer antidepressants
to patients not responding satisfactorily to previ-
ous treatments, and to those more likely to have
complex illnesses, has been documented elsewhere
[3,41]. The potential existence of channeling bias
when making statistical efficacy and cost compari-
sons among drugs was emphasized almost a de-
cade ago [42], and its impact has also been docu-
mented as occurring in therapeutic areas other
than antidepressants [43]. The 1995 to 1996 data
examined in this study are not as likely to be sub-
ject to this channeling bias when comparisons are
made among fluoxetine, paroxetine, and sertra-
line.
While our evidence is somewhat mixed regard-
ing the cost consequences of index SSRI choice on
total depression-related and total health care costs,
a robust finding is that SSRI pharmaceutical ac-
quisition costs are significantly lower for sertraline
and paroxetine when compared to fluoxetine.
This difference is not explained by simple titration
variations, for all else equal, while paroxetine is
less likely to be titrated than fluoxetine, no signifi-
cant difference in titration probabilities is associ-
ated with the choice of sertraline versus fluoxetine
as the index SSRI.
Two major factors contribute to the higher
pharmaceutical costs associated with choice of flu-
oxetine as the index SSRI. First, sertraline and flu-
oxetine have equal probabilities of being titrated,
but the consequences of titration vary by com-
pound in a critical manner. Whether titration re-
sults in a daily dose requiring one, two, three or
more tablets/capsules per day depends on the
range of dosage strengths offered by the SSRI
manufacturer. During the 1995 to 1996 study pe-
riod, fluoxetine capsules were available in 10 and
20 mg doses, paroxetine tablets in 20 and 30 mg
doses, and sertraline tablets in 50 and 100 mg
doses. Since the mean final dose in the treatment
period was 26.2, 24.9, and 85.2 mg for fluoxetine,
paroxetine, and sertraline, respectively, a signifi-
cant proportion of fluoxetine patients required at
least two capsules per day. Logistic regression
analyses indicated the probability of a patient be-
ing given an SSRI prescription during the 12-
month treatment period requiring a daily dosage
of two or more tablets/capsules was significantly
lower for sertraline and paroxetine than for fluox-
etine—odds ratios of 0.529 and 0.388 (P  .001),
respectively.
Second, the cost consequences of this higher
multiple-tablet daily regimen for fluoxetine de-
pend on how the various strengths of the com-
pounds are priced. In the 1995 to 1996 US data
examined in this study, all three SSRI manufactur-
ers had implemented flat pricing where similar
prices were charged for each tablet/capsule, re-
gardless of strength. Mean costs for fluoxetine 10
and 20 mg capsules were $2.00 and $2.02, for
paroxetine 20 and 30 mg tablets were $1.76 and
$1.78, and for sertraline 50 and 100 mg tablets
were $1.86 and $1.91, respectively. The combina-
tion of higher multiple-tablet dosing for fluoxetine
and flat pricing for all three SSRIs thereby resulted
in the observed higher daily medication costs for
fluoxetine.
Table 6 Ordered probit quartile parameter estimates of twelve-month treatment period depression-related costs (1 is 
lowest cost quartile, 4 is highest cost quartile)*†
Depression-Related Health Care Costs
Hospitalization Outpatient Antidepressants Total
Intercept1 0.010 0.177 0.274 0.433
Intercept2 0.6893 0.8303 0.6913 0.7483
Intercept3 1.3833 1.6753 1.3873 1.5283
Age 0.0362 0.0352 0.0473 0.0482
Agesq 0.0002 0.0013 0.0013 0.0013
Female 0.097 0.197 0.052 0.138
Age*Female 0.001 0.004 0.002 0.003
Comorbid 0.0661 0.044 0.0571 0.057
Comorbidsq 0.0051 0.002 0.005 0.003
Precost 0.045 0.4253 0.056 0.3563
Precostsq‡ 0.005 0.0183 0.005 0.0123
Psyprovider 0.2073 1.2673 0.2093 0.9043
Paroxetine 0.4253 0.042 0.4333 0.1821
Sertraline 0.3023 0.034 0.3193 0.2253
*1, 2, and 3 denote statistical significance at P-values less than or equal to 0.05, 0.01 and 0.001 respectively, based on z-test.
†Observations by quartile: n1  585, n2  586, n3  585, n4  586.
‡Precost is in thousands of dollars, Precostsq in millions of dollars.
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We find that in the naturalistic setting utilizing
RACD data, choice of index SSRI is nonrandom.
We believe SSRI choice is affected by a number of
factors, including patient clinical characteristics
(i.e., comorbidities, anxiety, lethargy, pharmaco-
kinetic interactions with other medications, etc.),
physician experience and knowledge, and length
of time an agent has been on the market. In con-
trast to Hylan et al. [7], we find that selective,
nonrandom SSRI choice is uncorrelated with total
depression-related and total health care expendi-
tures. This conclusion may, however, simply re-
flect the fact that implementation of the Heckman
sample selectivity procedure may have corrected
for only a subset of patient/physician characteris-
tics, many of which are unobserved and are only
imperfectly correlated with observed variables.
Our implementation of sample selectivity tech-
niques follows procedures generally followed by
others, but the extent to which these techniques
control reliably for nonrandom selection remains
a matter of some controversy [30–34,39]. Al-
though we have implemented a variety of alterna-
tive statistical techniques, there may be unob-
served or unknown factors that may have affected
our findings, and this absence of evidence is not
necessarily evidence of absence.
Several other methodological issues are worth
noting. Use of the Belsley-Kuh-Welsch [35] proce-
dure for identifying influential observations re-
sulted in a surprisingly small number of such ob-
servations being selected—from 0 to 22 in the raw
scale cost regressions, and 2–14 in the log-trans-
formed cost equations, less than 1%. It appears
therefore that a substantial proportion of observa-
tions with studentized residuals greater than two
in absolute value had only a roughly average im-
pact on parameter estimates. Since all our princi-
pal findings were unaffected by use of the BKW
procedure, we interpret this as providing some
support for the absence of overfitting in this data,
particularly in the log cost specifications, where
skewness measures were close to zero.
Regarding robustness to functional form, when
the regressor’s precost and its square were replaced
with their log transforms in the log cost equations,
estimates of and inference on the paroxetine and
sertraline coefficients were essentially unchanged.
Previous studies have varied in whether they fo-
cused on depression-related costs, or total health
care costs, or both [4–17]. When making treat-
ment cost comparisons, other things equal, health
economists generally prefer using more inclusive
measures of costs. It is possible, for example, that
reductions in nondepression related costs could
offset increases in depression-related costs. This
offset phenomenon has been reported in SSRI-
TCA cost comparisons [7,27]. In this study we
Table 7 Sample selection model parameter estimates*†
Log of Total Medical Costs the Dependent Variable
First Stage Multinominal Logit Second Stage OLS Estimates
Sertraline Paroxetine Fluoxetine Paroxetine Sertraline
Intercept 0.301 0.7322 6.3793 4.9073 6.8163
Age 0.002 0.000 0.001 0.026 0.025
Female 0.036 0.040 0.137 0.355 0.155
Agesq 0.000 0.000 0.000
Age*Female 0.006 0.007 0.002
DX296.3 0.1911 0.028
DX300.4 0.116 0.123
DX311 0.111 0.081
DX309 0.007 0.100
Comorbid 0.036 0.014 0.3213 0.2973 0.2843
Comorbidsq 0.0123 0.0071 0.0082
Hosp6 0.6302 0.313
Visit6 0.0292 0.018
Precost 0.000 0.000 0.000
Precostsq‡ 0.033 0.015 0.010
Psyprovider 0.102 0.005 0.3223 0.2203 0.2953
Lambda 0.079 1.009 0.632
Adjusted R2 na na 0.382 0.374 0.366
LR test§ 45413 na na na
N 2342 945 492 905
*Base case is male, ICD-9 diagnosis of 296.2, non-psychiatrist provider, treated with fluoxetine.
†1, 2, and 3 denote statistical significance at P-values less than or equal to 0.05, 0.01 and 0.001, respectively, based on z-test.
‡The coefficient on Precostsq is multiplied by E106.
§Likelihood ratio chi-square test that first stage coefficients (relative to fluoxetine) are simultaneously equal to zero. P-value 0.0008.
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found no evidence in support of offset differences
among the SSRIs. In particular, as can be seen
from detailed examination of Table 2, mean cost
differences between fluoxetine and paroxetine, be-
tween fluoxetine and sertraline, and between ser-
traline and paroxetine all steadily increase as one
successively compares antidepressant Rx costs, to-
tal depression-related costs, and total health care
costs. The statistical significance of differences,
however, does not sharpen as the cost measure be-
comes more inclusive, for sample standard devia-
tions generally increase proportionally more than
means (coefficients of variation rise) as the cost
measure is generalized. Although one might there-
fore expect the power of a test for differences
among SSRIs to decline as the cost measure ex-
pands, for the log of total health care cost equa-
tions we were still able to detect a statistically sig-
nificant difference between fluoxetine and sertraline
(P  .001), although none was found between flu-
oxetine and paroxetine.
Several other caveats are worth noting. As with
other retrospective claims analyses, a limitation of
this study is that disease severity and clinical out-
comes are unknown. Our cost measures are direct
health care costs, and exclude potentially very sig-
nificant indirect costs and benefits, such as func-
tional impairment and work productivity. More-
over, our direct health care cost measures are
societal in that they represent the sum of the pa-
tient’s actual copay/coinsurance payment plus that
by the insurer, to providers. Analyses focused only
on direct patient payments, or solely on third party
insurer payments, may yield different results.
Our purpose in this study has been to begin to
explain and reconcile the mixed SSRI cost com-
parison evidence in the existing literature. In do-
ing this, we have examined the robustness of find-
ings using alternative procedures employed in
other SSRI studies, but with a data set from a
common source. It would be useful and informa-
tive to implement other and more recently intro-
duced procedures with the same data set. In partic-
ular, quantile regression methods, sample selectivity
procedures in which the first stage assumption of
the independence of irrelevant alternatives is re-
laxed, alternative retransformation methods, and
methods that avoid retransformation entirely, all
merit further investigation to assess robustness of
findings. Many of these procedures are discussed
in Manning and Mullahy (unpublished data, July
1999).1 Regarding retransformation with hetero-
skedasticity, however, in the log-cost second stage
regressions reported in Table 7, there was no evi-
dence supporting heteroskedasticity by SSRI, for
the root mean squared errors varied by less than
3%–0.762 for fluoxetine, 0.749 for paroxetine,
and 0.770 for sertraline. Moreover, though not re-
ported there, P-values on the paroxetine and ser-
traline coefficients in the White test for homoske-
dasticity indicated lack of significance (P  0.48
in depression-related log costs, and  0.28 in total
health care log costs).
Future research might also focus on the extent
to which findings from this study can be replicated
with other publicly available databases using more
recent data, and if findings change materially when
the treatment period is expanded from 12 to 24 or
36 months.
This research was supported in part by Pfizer, Inc.
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